These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34787884)

  • 1. Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-19.
    Quagliariello V; Paccone A; Iovine M; Cavalcanti E; Berretta M; Maurea C; Canale ML; Maurea N
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6797-6812. PubMed ID: 34787884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Prevent Cardiotoxicity.
    Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
    Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced cardiomyopathy.
    Higgins AY; O'Halloran TD; Chang JD
    Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
    Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
    CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardio-oncology: the new frontier of clinical and preventive cardiology.
    Paris S; Tarantini L; Navazio A; Faggiano P
    Monaldi Arch Chest Dis; 2020 Jun; 90(2):. PubMed ID: 32571000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity: SGLT-2 inhibitors and chemotherapy-induced cardiotoxicity.
    Vafa RG; Sabahizadeh A; Mofarrah R
    Curr Probl Cardiol; 2024 Mar; 49(3):102350. PubMed ID: 38128634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines.
    Shiga T; Hiraide M
    Curr Treat Options Oncol; 2020 Mar; 21(4):27. PubMed ID: 32266582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
    Tajiri K; Aonuma K; Sekine I
    Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units].
    Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G
    Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.
    Jain D; Russell RR; Schwartz RG; Panjrath GS; Aronow W
    Curr Cardiol Rep; 2017 May; 19(5):36. PubMed ID: 28374177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of cardiovascular complications secondary to medical treatment of cancer].
    Banke A; Polk A; Nielsen D; Videbæk L; Overgaard U; Fosbøl EL; Vaage-Nielsen M; Nielsen KM; Schou M
    Ugeskr Laeger; 2018 Feb; 180(7):. PubMed ID: 29465031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological foundations of cardio-oncology.
    Minotti G; Salvatorelli E; Menna P
    J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M; Duarte-Rodrigues J; Campelo M
    Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
    Yeh ET; Tong AT; Lenihan DJ; Yusuf SW; Swafford J; Champion C; Durand JB; Gibbs H; Zafarmand AA; Ewer MS
    Circulation; 2004 Jun; 109(25):3122-31. PubMed ID: 15226229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
    Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
    Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative stress in anticancer therapies-related cardiac dysfunction.
    Attanasio U; Pirozzi F; Poto R; Cuomo A; Carannante A; Russo M; Ghigo A; Hirsch E; Tocchetti CG; Varricchi G; Mercurio V
    Free Radic Biol Med; 2021 Jun; 169():410-415. PubMed ID: 33930514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
    Cvetković RS; Scott LJ
    Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.